SAGE-217

Unassigned

New Medicines

Post-partum depressive disorder

Information

New molecular entity
SAGE Therapeutics
SAGE Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Selective positive allosteric modulator of GABAA receptors
Postpartum depression is estimated to occur in 10 to 15% of mothers in the developed world [2].
Post-partum depressive disorder
Oral